Novo Nordisk Partners With Anthropic to Speed Drug Development With AI
Summary
Novo Nordisk partners with Anthropic to accelerate drug development with AI as CEO Mike Doustdar pushes to make the company the world’s most AI-driven healthcare business amid fierce obesity-market competition.
Key Points
- Novo Nordisk and Anthropic partner to use artificial intelligence to speed drug development.
- Novo pursues the collaboration as it tries to catch up in the intensely competitive obesity market.
- CEO Mike Doustdar says Novo aims to become the world’s most AI-driven healthcare company.